We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

77 hedge funds and large institutions have $512M invested in Pliant Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 18

0.98% less ownership

Funds ownership: 85.51% → 84.53% (-0.98%)

5% less funds holding

Funds holding: 81 → 77 (-4)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

43% less capital invested

Capital invested by funds: $893M → $512M (-$381M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $812K

Holders
77
Holders Change
-4
Holders Change %
-4.94%
% of All Funds
1.35%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
7
Increased
30
Reduced
18
Closed
11
Calls
–
Puts
$812K
Net Calls
-$812K
Net Calls Change
-$623K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.12M
2
Citadel Advisors
Citadel Advisors
Florida
+$2.76M
3
Morgan Stanley
Morgan Stanley
New York
+$2.49M
4
CA
CHI Advisors
New York
+$2.48M
5
WP
Woodline Partners
California
+$2.3M

Top Sellers

1
FCM
Farallon Capital Management
California
-$14.3M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.13M
3
EAM
Eventide Asset Management
Massachusetts
-$6.13M
4
RG
Redmile Group
California
-$1.55M
5
SFM
Sphera Funds Management
Israel
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
51
MetLife Investment Management
New Jersey
$160K – – –
MLICM
52
Metropolitan Life Insurance Company (MetLife)
New York
$123K – – –
VEA
53
Virtus ETF Advisers
New York
$109K -$7.07K -333 -5%
Legal & General Group
54
Legal & General Group
United Kingdom
$97K +$52.1K +2,454 +74%
Citigroup
55
Citigroup
New York
$83K +$15K +708 +17%
GWM
56
Geneos Wealth Management
Colorado
$53K – – –
SO
57
STRS Ohio
Ohio
$50K – – –
ED
58
Exane Derivatives
France
$48.9K +$63.1K +2,971 New
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$40K +$15.8K +743 +45%
AIP
60
Ameritas Investment Partners
Nebraska
$33K – – –
UBS Group
61
UBS Group
Switzerland
$32K +$11.3K +533 +38%
PA
62
Parallel Advisors
California
$15K +$5.2K +245 +37%
PCM
63
Penserra Capital Management
California
$13K +$106 +5 +0.6%
SIC
64
Salem Investment Counselors
North Carolina
$13K +$15.4K +725 +1,036%
US Bancorp
65
US Bancorp
Minnesota
$12K +$2.08K +98 +16%
LC
66
Lindbrook Capital
California
$12K +$14.9K +700 New
TRCT
67
Tower Research Capital (TRC)
New York
$11K -$18.8K -884 -56%
Canada Life
68
Canada Life
Manitoba, Canada
$11K – – –
SOW
69
State of Wyoming
Wyoming
$10K -$7.77K -366 -37%
HI
70
Harbour Investments
Wisconsin
$6K +$658 +31 +9%
Wells Fargo
71
Wells Fargo
California
$4K -$882K -41,536 -99%
First Manhattan
72
First Manhattan
New York
$3K – – –
LWANC
73
Laurel Wealth Advisors (North Carolina)
North Carolina
$3K – – –
Daiwa Securities Group
74
Daiwa Securities Group
Japan
$2K +$1.19K +56 +84%
CA
75
Clearstead Advisors
Ohio
$1K – – –
1 2
3
4

PLRX Hedge Fund Activity: Q3 2021 in Review

77 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2021, worth a combined $512M — down 43% from $893M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PLRX and 7 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 30 added.

The largest buyer was Vanguard Group, adding an estimated $3.12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $14.3M sold.

  • 77 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2021, down from 81 in Q2 2021.
  • Funds reported $512M of Pliant Therapeutics stock for Q3 2021, down 43% quarter-over-quarter.
  • 7 funds opened new Pliant Therapeutics positions in Q3 2021 and 11 closed out, a net change of -4 holders.
  • The largest Pliant Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $3.12M added.
  • The largest Pliant Therapeutics seller in Q3 2021 was Farallon Capital Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q3 2021.